Charles River Laboratories (NYSE:CRL) announced that it completed a $292.5 million acquisition of Vigene Biosciences.
Rockville, Md.-based Vigene, a gene therapy contract development and manufacturing organization (CDMO), develops viral vector-based gene delivery systems, with a primary area of expertise in CGMP viral vector manufacturing for gene therapies and gene-modified cell therapies.
Get the full story at our sister site, Drug Delivery Business News.
Filed Under: Drug Delivery, Drug Discovery, Drug Discovery and Development
